Guselkumab in the treatment of inflammatory bowel diseases

Abstract

Guselkumab is a human monoclonal antibody IgG1 targeted to the IL-23p19 subunit engaging receptor CD64, inducing neutralization of IL-23, and capturing of IL-23 in the myeloid cells. Positive results from registration studies QUASAR and GALAXI allowed an approval of guselkumab for clinical practice in patients with moderately to severely active ulcerative colitis and Crohn’s disease. In these studies, a high safety drug profile was also confirmed. The same dosage for both diseases and subcutaneous induction significantly differentiate guselkumab from other anti-IL-23p19 inhibitors.